Target
Cytochrome P450 2C19
Ligand
BDBM50572809
Substrate
n/a
Meas. Tech.
ChEMBL_2118303 (CHEMBL4827369)
IC50
>10000±n/a nM
Citation
 Liang, JZbieg, JRBlake, RAChang, JHDaly, SDiPasquale, AGFriedman, LSGelzleichter, TGill, MGiltnane, JMGoodacre, SGuan, JHartman, SJIngalla, ERKategaya, LKiefer, JRKleinheinz, TLabadie, SSLai, TLi, JLiao, JLiu, ZMody, VMcLean, NMetcalfe, CNannini, MAOeh, JO'Rourke, MGOrtwine, DFRan, YRay, NCRoussel, FSambrone, ASampath, DSchutt, LKVinogradova, MWai, JWang, TWertz, IEWhite, JRYeap, SKYoung, AZhang, BZheng, XZhou, WZhong, YWang, X GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer. J Med Chem 64:11841-11856 (2021) [PubMed]  Article 
Target
Name:
Cytochrome P450 2C19
Synonyms:
(R)-limonene 6-monooxygenase | (S)-limonene 6-monooxygenase | (S)-limonene 7-monooxygenase | CP2CJ_HUMAN | CYP2C19 | CYPIIC17 | CYPIIC19 | Cytochrome P450 2C19 (CYP2C19) | Cytochrome P450 2C19 [I331V] | Cytochrome P450-11A | Cytochrome P450-254C | Fenbendazole monooxygenase (4'-hydroxylating) | Mephenytoin 4-hydroxylase | P450-11A | P450-254C
Type:
Enzyme
Mol. Mass.:
55935.47
Organism:
Homo sapiens (Human)
Description:
P33261
Residue:
490
Sequence:
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKIYGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRWKEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICSIIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFMESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTETTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRGHMPYTDAVVHEVQRYIDLIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFKKSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVPPFYQLCFIPV
  
Inhibitor
Name:
BDBM50572809
Synonyms:
CHEMBL4866043
Type:
Small organic molecule
Emp. Form.:
C27H30F6N4O
Mol. Mass.:
540.5437
SMILES:
C[C@@H]1Cc2c([nH]c3ccc(F)cc23)[C@H](N1CC(F)(F)CO)c1c(F)cc(NC2CN(CCCF)C2)cc1F |r|
Structure:
Search PDB for entries with ligand similarity: